^
Association details:
Biomarker:CLDN18.2 positive
Cancer:Gastric Cancer
Drug:AB011 (CLDN18.2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Excerpt:
...Tumor tissue samples is CLDN18.2 positive;...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors.

Published date:
01/17/2023
Excerpt:
Among 23 pts who had at least one tumor assessment by the data cut-off, 8/13 (61.5%) in 20mg/kg group and 7/10 (70%) in 30mg/kg group achieved PR. The ORR and DCR were 65.2% and 100% respectively….These results indicate that AB011, either in monotherapy or combined with chemotherapy, had a manageable safety profile and encouraging efficacy in CLDND18.2 positive advanced GC/GEJA and PC.
Secondary therapy:
CAPOX
DOI:
10.1200/JCO.2023.41.3_suppl.391
Trial ID: